The AllCells Blog

AllCells Blog

AllCells blog posts are dedicated to highlighting scientific trends, innovation, and technological advances within the biomedical industry. Data-driven studies and primary research are conducted to create our blogs and include experts within the following fields: immuno-oncologists, cell and gene therapy, academia, government, and contract research organizations.

AllCells Announces First to Market Launch of In Stock GMP-Compliant Cryopreserved Leukopaks

January 28, 2022

Collected from qualified healthy donors that meet baseline FDA 21 CFR 1271 requirements, industry’s first In Stock GMP-compliant Cryopreserved Leukopaks significantly decrease lead time AllCells, the industry leader in the […]

AllCells cryopreserved cells in vial

FAQ Series: The Science Behind Cryopreservation

January 11, 2022

Primary cells, such as those isolated from the bone marrow or peripheral blood, are important for a wide scope of research and clinical applications – from studying molecular mechanisms driving disease progression, to […]

AllCells GMP compliant Leukopak cells

GMP-Compliant Leukopaks for Allogeneic Cell Therapies

December 13, 2021

Adoptive cell therapies (ACTs), which is a treatment based on transferring cells (most often immune cells) into a patient, have revolutionized the standard of care to treat a broad range […]

AllCells GMP cryopreserved leukopak

GMP-Compliant Leukopaks Mitigate Risk in Cell and Gene Therapy Workflows

December 13, 2021

Isolated human primary cells are able to retain the morphological and functional characteristics of their tissue of origin, which makes them invaluable tools in life sciences to advance our understanding […]

AllCells' Cleanroom

AllCells Announces New GMP Cleanroom

December 13, 2021

Expansion of GMP capabilities to support the rapidly growing cell and gene therapy industry AllCells Alameda, CA Expands GMP Processing Capabilities AllCells, the industry leader in the procurement and customization […]

AllCells Bone Marrow

T Lymphocytes: A Look at their Role and Research Applications

September 15, 2021

T cells are the main effector cells of the adaptive immune system and can be distinguished from other white blood cells by the presence of a T-cell receptor (TCR) on […]


Addition of Eurofins Donor and Product Testing

August 31, 2021

Alameda, CA – August 31, 2021. AllCells is committed to providing the best-in-class third-party services complementary to our high-quality products. Due to the increasing demand for extended donor testing, we […]

B-cell, an antibody-producing cell of the immune system

B Cells: More Than Just Antibodies

August 13, 2021

B cells are lymphocytes that are part of the adaptive humoral immune system and are best known for their ability to produce antigen-specific antibodies. B cells express B cell receptors […]

CD34+ bone marrow histology

FAQ Series: Comparison of CD34+ Cells from Different Tissue Sources

July 16, 2021

Welcome to the second installment of our FAQ blog series! Today, we are looking at differences between CD34+ cells isolated from different tissue sources to provide a better understanding of […]

AllCells clinical grade bone marrow stem cells

Clinical Applications of Bone Marrow-Derived Mesenchymal Stem Cells

June 17, 2021

While next generation cell-based treatments like CAR-T immunotherapies have been the source of much excitement and clinical investment in recent years, cellular therapies have a long, established history in the […]

Subscribe to Our Blog

Stay current with the AllCells Blog. Get email updates with helpful resources for biomedical researchers:

Customer Service

How Can We Help You?

Looking for research tips? Need help sourcing materials? How about a few more articles on therapies or processes? At AllCells, we believe that partnerships create the best pathways to success. Our Customer Success Team has years of industry experience and a wealth of resources to help you get the most out of your cellular products. We’re only a few clicks away.

Contact Us
Have a question? Let’s chat.